What is NDC 68817-134?

68817-134 is the product NDC for Abraxane (paclitaxel), Paclitaxel 100 mg/20mL injection, powder, lyophilized, for suspension, listed with the FDA by Abraxis BioScience, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.

Abraxis BioScience, LLC, NDC labeler code 68817. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Abraxane?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Abraxane NDC 68817-134 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)68817-134Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68817-0134Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68817-134-50	68817013450	1 VIAL, SINGLE-USE in 1 CARTON (68817-134-50) / 20 mL in 1 VIAL, SINGLE-USEMarketed from Feb 10, 2005

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Abraxane
Generic name (nonproprietary): paclitaxel
Active ingredients: Paclitaxel — 100 mg/20mL
Dosage form: Injection, Powder, Lyophilized, For suspension
Route: Intravenous
Labeler: Abraxis BioScience, LLCNDC labeler code 68817
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 021660
Marketing start: Feb 10, 2005
Listing expires: Dec 31, 2027
Other FDA classes: Microtubule Inhibition (Physiologic effect)
Identifiers: Product ID 68817-134_d1c7770f-7099-4ad3-84e2-20e638cb224eSPL ID d1c7770f-7099-4ad3-84e2-20e638cb224eSPL set ID 24d10449-2936-4cd3-b7db-a7683db721e4RxCUI 583214, 583218UNII P88XT4IS4DUPC 0368817134500
Pharmacologic class: Microtubule Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N468817013450 followed by a unit qualifier and the quantity

Package 68817-0134-50. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 31, 2022. This label includes a boxed warning.

Indications (excerpt from the label)

ABRAXANE is a microtubule inhibitor indicated for the treatment of: • Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. ( 1.1 ) • Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. ( 1.2 ) • Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine. ( 1.3 ) 1.1 Metastatic Breast Cancer ABRAXANE is indicated for the treatment …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 68817-134

What is NDC 68817-134?: 68817-134 is the product NDC for Abraxane (paclitaxel), Paclitaxel 100 mg/20mL injection, powder, lyophilized, for suspension, listed with the FDA by Abraxis BioScience, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Abraxane (Paclitaxel).
What is the active ingredient?: Paclitaxel.
Who is the labeler?: Abraxis BioScience, LLC, NDC labeler code 68817. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Abraxane?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Abraxane (Paclitaxel) NDC 68817-134